22160-08-3

Basic information

• Product Name: (R)-(-)-Coniine
• Synonyms: (R)-(-)-Coniine;(R)-2-ETHYLPIPERIDINE-HCL
• CAS NO: 22160-08-3
• Molecular Formula: C₇H₁₅N
• Molecular Weight: 113.202
• Mol File: 22160-08-3.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (R)-(-)-Coniine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-(-)-Coniine(22160-08-3)
• EPA Substance Registry System: (R)-(-)-Coniine(22160-08-3)

Safety Data

• Hazardous Substances Data: 22160-08-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
(R)-(-)-Coniine is utilized as a subject of research in the pharmaceutical industry for its potential medicinal properties, specifically in the exploration of treatments for neurological disorders such as Alzheimer's disease. (R)-(-)-Coniine's interaction with nicotinic acetylcholine receptors offers a pathway for studying its effects on cognitive functions and neurodegenerative processes.
Used in Toxicological Studies:
In the field of toxicology, (R)-(-)-Coniine serves as a model compound for understanding the mechanisms of action of nicotinic acetylcholine receptor antagonists. This helps in the development of antidotes and treatments for poisoning incidents, as well as in the broader study of neuromuscular function and paralysis.
Used in Forensic Analysis:
(R)-(-)-Coniine is employed in forensic science for the detection and analysis of poisoning cases, particularly in historical or high-profile investigations where the compound may have been used as a poison. Its distinctive chemical properties and historical significance make it a relevant substance in forensic toxicology.
Used in Educational Settings:
In educational contexts, particularly in chemistry and biology courses, (R)-(-)-Coniine is used as a teaching tool to illustrate the concepts of chemical toxicity, receptor antagonism, and the historical use of poisons. It provides a real-world example of how chemical structure influences biological activity and the potential dual-use of substances in both harmful and therapeutic contexts.

Upstream product

• 1484-80-6 2-ethylpiperidine 
• 1643770-97-1 (S)-2,2-dimethyl-5-oxo-3-(2-phenylacetyl)imidazolidin-1-yl 2-methoxy-2-phenylacetate 

Downstream Products

• 84028-92-2 (2R,2'R)-2-(2-Ethylpiperidino)-3-phenyl-propionsaeure-methylester 
• 1417826-84-6 (R)-1-(2-ethylpiperidin-1-yl)-3-phenylpropan-1-one 
• 81013-97-0 (-)-R-trans-N-[β-(2-Methyl-6-phenyl-imidazo[2,1-b]-1,3,4-thiadiazol-5-yl)-propenoyl]-2-ethyl-piperidine 

Relevant articles and documents

Stereoelectronic basis for the kinetic resolution of n-heterocycles with chiral acylating reagents

The kinetic resolution of N-heterocycles with chiral acylating agents reveals a previously unrecognized stereoelectronic effect in amine acylation. Combined with a new achiral hydroxamate, this effect makes possible the resolution of various N-heterocycles by using easily prepared reagents. A transition-state model to rationalize the stereochemical outcome of this kinetic resolution is also proposed.

Expanded substrate scope and catalyst optimization for the catalytic kinetic resolution of N-heterocycles

The scope, reactivity, and selectivity of the chiral hydroxamic acid-catalyzed kinetic resolution of chiral amines are improved by a new catalyst structure and a more environmentally friendly reaction protocol. In addition to increasing selectivity across all substrates, these conditions make possible the resolution of N-heterocycles containing lactams or other basic functional groups that can inhibit the catalyst.

THERAPEUTIC COMBINATIONS COMPRISING A SELECTIVE ESTROGEN RECEPTOR MODULATOR AND A SELECTIVE ANDROGEN RECEPTOR MODULATOR

This invention relates to a pharmaceutical combination of a selective estrogen receptor modulator (SERM) and a selective androgen receptor modulator (SARM). Particularly, this invention relates to a pharmaceutical composition comprising cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetrahydronapthalene-2-ol, or a pharmaceutically acceptable salt thereof; and a selective androgen receptor modulator. This invention also relates to methods of treatment using the pharmaceutical composition comprising cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetrahydronapthalene-2-ol, or a pharmaceutically acceptable salt thereof; and a selective androgen receptor modulator. Particularly, this invention is directed to methods to prevent and/or restore age-related decline in muscle mass and strength, treat a wasting disease, treat a condition that prevents with low bone mass, increase muscle mass, increase lean body mass, decrease fat body mass, treat bone fracture and muscle damage and treat female sexual dysfunction in mammals, including humans.

BENZONITRILE DERIVATIVES TO TREAT MUSCULOSKELETAL FRAILTY

This invention relates to novel amino substituted benzonitrile derivatives and to pharmaceutical compositions containing the novel amino substituted benzonitrile derivatives. This invention also relates to methods of treatment using amino substituted benzonitrile derivatives to prevent and/or restore age-related decline in muscle mass and strength, treat a wasting disease, treat a condition that prevents with low bone mass, increase muscle mass, increase lean body mass, decrease fat body mass, and treat bone fracture and muscle damage in mammals, including humans.